Akebia Therapeutics, Inc.
AKBA
$1.18
$0.032.61%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 26.05% | -2,367.41% | 118.62% | -95.96% | 126.80% |
| Total Depreciation and Amortization | 2.18% | 0.94% | 0.63% | 0.64% | -96.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.06% | 164.10% | -51.92% | 71.75% | -20.54% |
| Change in Net Operating Assets | -212.21% | 13.75% | 277.00% | 117.16% | -820.02% |
| Cash from Operations | -168.13% | 10.76% | 25.78% | 264.46% | -204.23% |
| Capital Expenditure | 11.43% | 9.09% | 38.89% | -600.00% | -800.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 99.21% | -10,129.87% | 38.89% | -181.82% | 7,800.00% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 84.46% | -- | -- | 100.00% | -46,300.00% |
| Issuance of Common Stock | 139.68% | -94.34% | -35.29% | -97.37% | 193.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 57.07% | -- | -- | 100.00% | -- |
| Cash from Financing | 80.90% | -535.58% | -35.29% | -97.70% | 235.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -220.60% | -36.84% | 21.73% | -61.08% | 244.45% |